title: Utilization and evaluation of noncore chemotherapy regimens within an academic medical center.
abstract: Uniformity of evidence-based chemotherapy prescribing using approved, standard, or "core" regimens provides systems-based safety. Noncore chemotherapy regimens are non-standard-of-care regimens requested by physicians on a patient-by-patient basis. Chemotherapy Council, a Pharmacy & Therapeutics subcommittee, assesses all requests and determines approval status based upon submitted evidence and patient-specific factors. This study's purpose is to describe noncore chemotherapy regimens utilization, efficacy, and clinical outcomes in patients receiving noncore chemotherapy regimens. This retrospective chart review includes a two-stage utilization and outcomes evaluation of patients receiving noncore chemotherapy regimens. Stage I, a demographics and utilization assessment of patients receiving noncore chemotherapy regimens, has data collection including patient age, sex, performance score, malignancy, and noncore chemotherapy regimen use justification. Stage II assesses noncore chemotherapy regimen-related, patient-specific outcomes of breast cancer noncore chemotherapy regimen patients. Breast cancer patients were evaluated on regimen and clinical outcomes including disease stage, regimen duration, discontinuation reason, subsequent chemotherapy, survival, and time from noncore chemotherapy regimen until death. Within stage I, 307 patient-specific noncore chemotherapy regimen requests were submitted. The most commonly submitted rationale was modification of a core regimen (33%), followed by patient-specific factors (29%) and salvage therapy (22%). For stage II, 29 breast cancer patients received a noncore chemotherapy regimen and most (54%) received a modified core regimen. The vast majority of noncore chemotherapy regimen discontinuation was due to either regimen completion (42%) or disease progression (42%). Nonelective hospitalizations (35%) and mortality (30%) were found during the median 13.3 months of follow up. Noncore chemotherapy regimen use provides regimen tailoring for patients who are candidates for further therapy, but nonelective hospitalizations, end-of-life chemotherapy, and mortality warrant further investigation to improve patient outcomes.
authors.affiliation: 1 University of Wisconsin Hospital and Clinics, Madison, WI, USA.
authors.forename: Jason R
authors.initials: JR
authors.lastname: Jared
authors.affiliation: 1 University of Wisconsin Hospital and Clinics, Madison, WI, USA.
authors.forename: Mary S
authors.initials: MS
authors.lastname: Mably
authors.affiliation: 2 University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
authors.forename: Rory
authors.initials: R
authors.lastname: Makielski
authors.affiliation: 1 University of Wisconsin Hospital and Clinics, Madison, WI, USA.
authors.forename: Michael P
authors.initials: MP
authors.lastname: Reed
authors.affiliation: 1 University of Wisconsin Hospital and Clinics, Madison, WI, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Fallon
authors.affiliation: 2 University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
authors.forename: Glenn
authors.initials: G
authors.lastname: Liu
authors.affiliation: 2 University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Mulkerin
authors.affiliation: 2 University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
authors.forename: Natalie S
authors.initials: NS
authors.lastname: Callander
mesh_terms: D000046:Academic Medical Centers; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D055815:Young Adult
keywords: Chemotherapy standardization; chemotherapy outcomes; noncore chemotherapy regimen